Hemant Chavan

Dr. Hemant Chavan is a Principal Scientist in the Translational Safety department at Genentech, where he supports portfolio programs across various therapeutic areas and drug modalities. Before joining Genentech, Dr. Chavan was the Director of Toxicology at Sana Biotechnology, providing nonclinical toxicology representation for Cell and Gene Therapy programs in multiple therapeutic areas. He also served as a Study Director in the Drug Safety Assessment group at Charles River Laboratories in Reno.

Dr. Chavan holds a Pharmacy degree and earned his PhD in Toxicology from the University of Kansas in 2013, followed by postdoctoral training at the Kansas University Medical Center from 2013 to 2017. His research has centered on the impact of the environmental toxicant arsenic on liver mitochondria, including understanding the role of mitochondria in arsenic toxicity and investigating the molecular mechanisms behind altered mitochondrial bioenergetics after arsenic exposure.

Dr. Chavan has published 22 peer-reviewed articles in esteemed journals such as Toxicological Sciences, Journal of Biological Chemistry, Human Gene Therapy, and PLoS One. He has received multiple awards and recognition from various scientific organizations, including the Society of Toxicology (SOT). He is also an editorial board member of Drug Metabolism Letters and serves as an ad hoc reviewer for several peer-reviewed journals.

Since 2017, Dr. Chavan has been a Diplomate of the American Board of Toxicology and has been a member of the Society of Toxicology since 2010. Additionally, he is an active volunteer in the SOT, having served as an officer for an SOT Regional Chapter/Specialty Section, and is committed to contributing further to the education, mentoring, and outreach efforts of the SOT.

2024-2025 Mentee: Yomilka Molina Cordero